infigratinib
bridgebio pharmaceutical
['proof 302', 'infigratinib', 'urothelial']
fgfr3 alterations in #proof 302: a phase iii trial of infigratinib (bgj398) as adjuvant therapy in patients with invasive #urothelialcarcinoma. presented by . #asco23 written coverage by &gt; 
Largest global online community of #urological medical professionals & patients. #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology